...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urologic oncology >PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma.
【24h】

PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma.

机译：Schwannoma中的PSMA表达：转移性前列腺癌的潜在临床模仿者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: Radioimmunoscintigraphy using a radiolabeled antibody against prostate-specific membrane antigen (PSMA) is frequently used to detect prostate carcinoma (PCa) recurrence and metastasis to lymph nodes, soft tissues, and bone. PSMA expression has been shown in occasional nonprostatic neoplasms (e.g., urothelial adenocarcinoma) and in the vasculatures of other malignancies. PSMA expression has not been described in benign neoplasms. Recently, during evaluation of a prostatic carcinoma patient, we encountered a false positive PSMA radioimmunoscintigraphy scan in a pathologically confirmed Schwannoma (SCH) lesion. The current study further evaluates PSMA expression in Schwannomas. METHODS: Eleven SCH were retrieved from our surgical pathology archives. Representative sections were immunostained with monoclonal antibody for PSMA. PSMA expression was evaluated in tumor cells and lesional vessels. Extent of staining was calculated as percent of positive cells in highest areas of expression. Positive staining was considered focal, multifocal, or diffuse based on the percent of positive cells: <5%, 5% to 75%, and >75%, respectively. RESULTS: All 11 SCH showed tumoral and or vascular staining; 7 (7/11) displayed both vascular and tumoral cell staining; the remaining 4 had only vascular staining (2/11) or tumor cell staining (2/11). The extent of tumoral cell and vascular staining varied widely among lesions (tumor cells: focal in 8 and diffuse in 1; vascular: focal in 7, multifocal in 1, and diffuse in 1 lesion). CONCLUSION: This is the first report of PSMA expression in a benign neoplasm. Given our finding of frequent expression of PSMA in Schwannomas, they should be clinically considered in the differential diagnosis of a lesion that is positive on PSMA radioimmunoscintigraphy study performed during a metastatic work-up of PCa patient.
机译：目的：使用放射性标记的抗前列腺特异性膜抗原（PSMA）抗体进行放射免疫闪烁照相术通常用于检测前列腺癌（PCa）的复发和转移至淋巴结，软组织和骨的转移。在偶然的非前列腺肿瘤（例如尿路上皮腺癌）和其他恶性肿瘤的脉管系统中已经显示出PSMA表达。在良性肿瘤中尚未描述PSMA表达。最近，在对一名前列腺癌患者进行评估期间，我们在经病理证实的神经鞘瘤（SCH）病变中遇到了假阳性的PSMA放射免疫闪烁扫描。当前的研究进一步评估了神经鞘瘤中PSMA的表达。方法：从我们的手术病理学档案中检索出11个SCH。用针对PSMA的单克隆抗体对代表性切片进行免疫染色。在肿瘤细胞和病变血管中评估PSMA表达。以最高表达区域中阳性细胞的百分比计算染色程度。基于阳性细胞的百分比，阳性染色被认为是局灶性，多灶性或弥漫性：分别<5％，5％至75％和> 75％。结果：所有11个SCH均显示出肿瘤和/或血管染色。 7（7/11）显示了血管和肿瘤细胞的染色;其余4只仅具有血管染色（2/11）或肿瘤细胞染色（2/11）。肿瘤细胞和血管染色的程度在病变之间差异很大（肿瘤细胞：局灶性在8个，弥散性在1个;血管：局灶性在7个，多灶性在1个，弥散在1个病变）。结论：这是良性肿瘤中PSMA表达的首次报道。鉴于我们发现了神经鞘瘤中PSMA频繁表达的发现，因此在对PCa患者进行转移性检查期间进行的PSMA放射免疫闪烁成像研究阳性的病变的鉴别诊断中，应在临床上考虑它们。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号